Business Context and Reporting Period
This Form 6-K filing by AC Immune SA covers the results of the Annual Ordinary Shareholders' Meeting held on June 28, 2017. The company is a foreign private issuer based in Lausanne, Switzerland, and files annual reports under Form 20-F.
Key Financial Metrics
The filing references financial data for the fiscal year ended 2016 but does not provide a comprehensive income statement, cash flow statement, or balance sheet details within this specific document.
- Net Loss (2016): KCHF 7,628 (7.628 million Swiss Francs).
- Accumulated Loss: The net loss was added to a prior loss brought forward of KCHF 24,930, resulting in a new accumulated loss balance of KCHF 32,558.
- Revenue, Cash Flow, Debt, Liquidity: The filing text does not provide clear values for these metrics.
Material Changes and Governance Actions
Shareholders approved the 2016 Annual Report and Financial Statements. Key governance and compensation decisions include:
- Board Compensation (FY 2017-2018): Approved maximum non-performance-related cash compensation of CHF 428,000 and equity/equity-linked instruments valued at up to CHF 451,000.
- Executive Committee Compensation (FY 2017-2018): Approved maximum non-performance-related cash compensation of CHF 1,554,000, variable compensation of CHF 782,000 for 2017, and equity/equity-linked instruments valued at up to CHF 3,472,000.
- Board Elections: Martin Velasco was re-elected as Chairman, alongside Peter Bollmann, Friedrich von Bohlen, Andrea Pfeifer, Detlev Riesner, and Thomas Graney.
- Auditor Re-election: Ernst & Young SA was re-elected for a one-year term.
Guidance, Outlook, and Risks
This filing is a report of shareholder meeting results and does not contain forward-looking guidance, management commentary on future operations, specific risk factors, or details on contingencies. The attached presentation (Exhibit 99.1) is referenced but its content is not included in the text provided.
Investor Verification Checklist
- Verify the full 2016 Annual Report and IFRS financial statements to assess revenue, cash burn, and liquidity positions not detailed here.
- Review the attached Exhibit 99.1 (Shareholders' Meeting Presentation) for strategic updates and pipeline progress.
- Confirm the impact of the approved executive compensation packages on future cash flow and dilution.
- Monitor the company's cash runway given the accumulated loss of KCHF 32,558.